T1	Participants 514 589	114 patients given alpha-interferon for chronic hepatitis B virus infection
T2	Participants 618 687	eceived a minimum of 90 million units per m2 total dose over 12 weeks
T3	Participants 691 749	negative anti-human immunodeficiency virus antibody status
T4	Participants 771 811	chronic active hepatitis on liver biopsy
T5	Participants 833 847	high AST level
T6	Participants 869 900	low hepatitis B virus DNA level
T7	Participants 927 953	history of acute hepatitis
T8	Participants 1678 1739	patients with chronic infection of less than 2 years duration
